Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00317603 · ClinicalTrials.gov registry record · Phase 1
Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00317603 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 15 participants.
The verdict
NCT00317603, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this trial is to test the safety of a vaccine made from a patient's own breast cancer cells, and determine if this vaccine will delay or stop the growth of the cancer. The vaccine is made by genetically modifying a patient's own tumor cells to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate the immune response.
Interventions
- BIOLOGICAL Autologous, Lethally Irradiated Breast Cancer Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-01-01 |
| Est. Completion | 2021-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00317603
The ClinicalTrials.gov registry entry for NCT00317603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous, Lethally Irradiated Breast Cancer Cells is the first listed.
NCT00317603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00317603 about?
NCT00317603 is a clinical study titled "Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients". The purpose of this trial is to test the safety of a vaccine made from a patient's own breast cancer cells, and determine if this vaccine will delay or stop the growth of the cancer. The vaccine is made by genetically modifying a patient's own tumor cells to secrete granulocyte-macrophage colony-sti...
What is the current status of trial NCT00317603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2006-01-01. Estimated completion is 2021-06.
What interventions are being tested in trial NCT00317603?
The interventions under investigation include: Autologous, Lethally Irradiated Breast Cancer Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00317603?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.